Literature DB >> 11489989

A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells.

V Screpanti1, R P Wallin, H G Ljunggren, A Grandien.   

Abstract

NK cells provide a line of defense against tumors and virus-infected cells that have lost the expression of one or more MHC class I isoforms. Here, we investigate whether inhibitors of apoptosis can block the rejection of tumors mediated by NK cells, by introducing the long form of Fas-associated death domain-like IL-1beta-converting enzyme-associated inhibitory protein (FLIP(L)) and poxvirus cytokine response modifier A (CrmA) into the MHC class I-deficient T lymphoma cell line RMA-S. RMA-S cells do not normally express Fas in vitro, and it was previously postulated that the rejection of these tumors by NK cells is strictly perforin dependent. We show that perforin-deficient NK cells directly mediate Fas up-regulation on RMA-S cells and thereafter kill the cells in a Fas-dependent manner, and that RMA-S FLIP(L) and RMA-S CrmA are protected from such killing. When injected in immunocompetent recipients, RMA-S cells up-regulate Fas, rendering in vivo-passed mock-transduced cells sensitive to Fas-mediated apoptosis. Moreover, RMA-S FLIP(L) and RMA-S CrmA cells establish aggressive tumors, in contrast to RMA-S mock cells that are rejected. These results demonstrate that FLIP(L) and CrmA function as tumor progression factors by protecting MHC class I-deficient tumors from rejection mediated by NK cells. Moreover, our data indicate that death receptor-mediated apoptosis has a more prominent role in the clearance of NK-sensitive tumors than previously suggested.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489989     DOI: 10.4049/jimmunol.167.4.2068

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.

Authors:  Sudha Neelam; Jessamee Mellon; Amber Wilkerson; Jerry Y Niederkorn
Journal:  Melanoma Res       Date:  2019-08       Impact factor: 3.599

Review 2.  Stromal-cell regulation of natural killer cell differentiation.

Authors:  Claude Roth; Carla Rothlin; Sylvain Riou; David H Raulet; Greg Lemke
Journal:  J Mol Med (Berl)       Date:  2007-04-11       Impact factor: 4.599

Review 3.  Immunobiology of the TAM receptors.

Authors:  Greg Lemke; Carla V Rothlin
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

Review 4.  Engineering Natural Killer Cells for Cancer Immunotherapy.

Authors:  Katayoun Rezvani; Rayne Rouce; Enli Liu; Elizabeth Shpall
Journal:  Mol Ther       Date:  2017-06-28       Impact factor: 11.454

Review 5.  The role of natural killer cells in tumor control--effectors and regulators of adaptive immunity.

Authors:  Morgan E Wallace; Mark J Smyth
Journal:  Springer Semin Immunopathol       Date:  2005-02-24

6.  Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.

Authors:  J Sträter; U Hinz; C Hasel; U Bhanot; G Mechtersheimer; T Lehnert; P Möller
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

7.  Essential role for hematopoietic Fas ligand (FasL) in the suppression of melanoma lung metastasis revealed in bone marrow chimeric mice.

Authors:  Christopher L Hall; Mike Yao; Laurie L Hill; Laurie B Owen-Schaub
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

8.  Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity.

Authors:  Julian J Lum; David J Schnepple; Zilin Nie; Jaime Sanchez-Dardon; Georgina L Mbisa; Jennifer Mihowich; Nanci Hawley; Shanil Narayan; John E Kim; David H Lynch; Andrew D Badley
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 9.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

Review 10.  Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses.

Authors:  Saar Gill; Janelle A Olson; Robert S Negrin
Journal:  Biol Blood Marrow Transplant       Date:  2009-04-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.